Is IDEXX Laboratories a good investment? Analyzing its consistent growth, innovative products, and international expansion ...

Baron Funds, an investment management company, released its “Baron Asset Fund” fourth quarter 2024 investor letter. A copy of ...

Conestoga Capital Advisors, an asset management company, released its fourth-quarter 2024 investor letter. A copy of the ...

Shares of IDEXX Laboratories Inc. IDXX rallied 1.02% to $449.06 Tuesday, on what proved to be an all-around positive trading ...

Idexx Laboratories exceeded earnings expectations for Q4 2024, buoyed by robust performance in its key diagnostic segments. Idexx Laboratories offers a variety of products and diagnostic services ...

Veterinary diagnostics specialist Idexx Laboratories (NASDAQ:IDXX) reported fourth-quarter earnings on Monday, Feb. 3, that topped analysts' consensus top- and bottom-line estimates. Revenue for ...

Idexx Labs' fourth-quarter results easily surpassed analysts' expectations. However, its even stronger guidance for 2025 may have stolen the show. Set to launch its newest diagnostic instrument in ...

IDEXX Laboratories, Inc.’s IDXX fourth-quarter performance was driven by the consistent strong performance of the Companion Animal Group (“CAG”) segment. Solid performance in the ...

Idexx Laboratories (IDXX) came out with quarterly earnings of $2.62 per share, beating the Zacks Consensus Estimate of $2.40 per share. This compares to earnings of $2.32 per share a year ago.

In a new SEC filing on February 11, it was revealed that Fennell, Executive Vice President at IDEXX Laboratories IDXX, executed a significant exercise of company stock options. What Happened ...

Piper Sandler analyst David Westenberg maintained a Hold rating on Idexx Laboratories (IDXX – Research Report) today and set a price target of $510.00. The company’s shares closed last Friday ...